Patterns-of-Failure Analysis of Patients with High Pretreatment Prostate-Specific Antigen Levels Treated by Radiation Therapy: The Need for Improved Systemic and Locoregional Treatment

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1093-1097

  Hanks, Gerald E ^a   Hanlon, Alexandra L ^a   Hudes, Gary ^a   Lee, W Robert ^a   Suasin, Winlove ^a   Schultheiss, Timothy E ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TREATMENT FAILURE; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 0029978346     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1093     Document Type: Article

References (37)

1. Catalona WJ, Richie JP, Ahmann FR, et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 151:1283-1290, 1994
2. Perez CA, Hanks GE, Leibel SA, et al: Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Int J Radiat Oncol Biol Phys 72:3156-3173, 1993
3. Catalona WJ, Smith DS, Ratliff TL, et al: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156-1161, 1991
4. Oesterling JE, Chan DW, Epstein JI, et al: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 139:766-772, 1988
5. Stamey TA, Yang N, Hay AR, et al: Prostate-specific antigen as a serum marker of adenocarcinoma of the prostate. N Engl J Med 317:909-916, 1987
6. Hanks GE, D'Amico A, Epstein B, et al: Prostatic-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling time. Int J Radiat Oncol Biol Phys 27:125-127, 1993
7. Hanks GE, Hanlon AL, Lee WR, et al: Pretreatment PSA doubling times: Clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys (in press)
8. Pisansky TM, Cha SS, Earle JD, et al: Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 11:2158-2166, 1993
9. Zeitman AL, Coen JJ, Shipley WU, et al: Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome. J Urol 151:640-645, 1994
10. Lee WR, Hanks GE, Schultheiss TE, et al: Localized prostate cancer treated by external beam radiotherapy alone: Serum PSA driven outcome analysis. J Clin Oncol 13:464-469, 1995
11. American Joint Commission on Staging of Cancer. Manual for Staging of Cancer (ed 4). Philadelphia, PA, Lippincott, 1992
12. Pinover WH, Hanlon A, Lee WR, et al: Prostate cancer patients upstaged by imaging and treated with irradiation: An outcome based analysis. Cancer (in press)
13. Hanks GE, Schultheiss TE, Hunt M: Clinical experience with 3D radiotherapy treating prostate cancer. Proceedings of International Symposium on 3D Radiation Treatment of Prostate Cancer, St Louis, MO, April 21-23, 1993
14. Hanks GE: Treatment of early stage prostate cancer, radiotherapy, in Hellman S, DeVita VT, Freeman S (eds): Important Advances in Oncology. Philadelphia, PA, Lippincott, 1993, pp 1073-1113
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:447-457, 1958
16. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
17. Cox DR: Regression methods and life tables (with discussion). J R Stat Soc 34:187-220, 1972
18. Zagars GK, von Eschenbach AC: Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy. Cancer 72:538-548, 1993
19. Turner JW, Hawes DR, Williams RD: Magnetic resonance imaging for detection of prostate cancer metastatic to bone. J Urol 149:1482-1484, 1993
20. Wood DP Jr., Banks ER, Humphreys S, et al: Identification of bone marrow micrometastases in patients with prostate cancer. Cancer 74:2533-2540, 1994
21. Zeitman AL, Shipley WU, Coen JJ, et al: Long-term outcome for men with prostate cancer treated with radiation as sole therapy. Int J Radiat Oncol Biol Phys 30:218, 1994 (abstr)
22. Hancock SL, Cox RS, Bagshaw MA: Biochemical control of prostate cancer and kinetics of prostate specific antigen in recurrences in a cohort of patients treated by external beam irradiation. Int J Radiat Oncol Biol Phys 30:217, 1994 (abstr)
23. Hanks GE, Lee WR, Corn B, et al: Response to "only 20% of irradiated prostate cancer patients are cured and the remainder may be made worse." Int J Radiat Oncol Biol Phys 30:217, 1994 (abstr)
24. D'Amico A, Hanks GE: Linear regressive analysis using PSA doubling time predicts tumor biology and clinical outcome in prostate cancer. Cancer 72:2638-2643, 1993
25. Hussain M, Wolf M, Marshall E, et al: Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A Southwest Oncology Group report. J Clin Oncol 12:1868-1875, 1994
26. Hanks GE, Lee WR, Hanlon AL, et al: Conformal technique dose escalation for prostate cancer: Improved cancer control with higher doses in patients with pretreatment PSA ≥ 10 ngm/ml. Int J Radiat Oncol Biol Phys (in press)
27. Fuks Z, Leibel SA, Wallner KE, et al: The effect of local control on metastatic dissemination in carcinoma of the prostate: Long term results in patients treated with I-125 implantation. Int J Radiat Oncol Biol Phys 21:537-547, 1991
28. Kuban DA, El-Mahdi AM, Schellhammer PF, et al: The significance of post-irradiation prostate biopsy with long-term follow-up. Int J Radiat Oncol Biol Phys 21:191, 1991 (abstr)
29. Zelefsky M, Leibel S, Burman C, et al: Early observations of acute and chronic toxicity and PSA response in patients with carcinoma of the prostate treated on a dose escalation study with 3D-CRT. Int J Radiat Oncol Biol Phys 30:156, 1994 (abstr)
30. Sandler HM, Perez-Tamayo C, Ten Haken RK, et al: Dose escalation for stage C (T3) prostate cancer: Minimal rectal toxicity observed using conformal therapy. Radiother Oncol 23:53-54, 1992
31. Hanks GE, Lee WR, Schultheiss TE: Clinical and biochemical evidence of control of prostate cancer at five years after external beam radiation. J Urol 154:456-459, 1995
32. Pilepich MV, Krall JM, Al-Sarraf M, et al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45:616-623, 1995
33. Pilepich MV, Caplan R, Byhardt RW, et al: Phase III trial of androgen suppression using Goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy (report of RTOG protocol #85-31). J Clin Oncol 14:239, 1995 (abstr)
34. Hanks GE: The challenge of treating node positive prostate cancer: An approach to resolving the questions. Cancer 71:1014-1018, 1993
35. Partin AW, Yoo J, Carter HB, et al: Use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:110-114, 1993 (abstr)
36. Hanks GE, Asbell S, Krall JM, et al: Outcome for lymph node dissection negative T-1b, T-2 (A-2, B) prostate cancer treated with external beam radiation therapy in RTOG 77-06. Int J Radiat Oncol Biol Phys 21:1099-1103, 1991
37. Rifkin MD, Zerhouni EA, Gatsonis CA, et al: Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. N Engl J Med 323:621-626, 1990